The Botswana Medicines Regulatory Authority (BoMRA) and the World Health Organization (WHO) are hosting a Good Clinical Practice (GCP) capacity-building workshop for clinical trial reviewers from regulatory authorities across Africa.
The programme, organised by the WHO Regional Office for Africa’s AVAREF Secretariat, Vaccine Research and Innovation Unit, and Disease Prevention and Control cluster, brings together regulators from Eswatini, Gambia, Liberia, Seychelles, Sierra Leone, and Zambia alongside BoMRA reviewers from clinical trials and pharmacovigilance.
The workshop focuses on hands-on GCP inspection aligned with the revised ICH E6(R3) standard adopted in 2025. Participants will conduct an on-site GCP inspection at a clinical trial site in Botswana, a first for several participating countries. The Paul-Ehrlich-Institut, Germany’s federal agency for vaccines and biomedicines, is supporting and funding the initiative.
Africa accounts for less than three per cent of global clinical trial activity despite carrying a quarter of the world’s disease burden. Ten of the continent’s fifty-five National Regulatory Authorities have reached WHO Maturity Level 3, the benchmark for a functional regulatory system.
Source: Botswana Medicines Regulatory Authority (BoMRA), “WHO and Botswana launch Good Clinical Practice (GCP) training of reviewers from Regulatory Authorities across the continent”, 21 September 2026: https://www.bomra.co.bw/who-and-botswana-launch-good-clinical-practice-gcp-training-of-reviewers-from-regulatory-authorities-across-the-continent/
